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The major focus regarding the lipid composition of biological mem-
branes and the roles of lipids in signal transduction has been on the na-
ture of the lipid headgroup. However, it is well established that the acyl
chain composition of lipids also has an important biological role. This is
at ﬁrst surprising since acyl chains are only hydrocarbons and do not
contain a variety of polar groups that can result in speciﬁc interactions.
An example of a speciﬁc role of an acyl chain is the ﬁnding that one spe-
ciﬁc acyl chain, the arachidonoyl (20:4) chain (Table 1 shows some acyl
chain structures) attached to phosphatidylcholine oscillates during the
cell cycle anddelays cell cycle progression as a consequence of inhibiting
the binding of Akt [1]. There are several mechanisms by which acyl
chains can modulate function. One mechanism is by changing the phys-
ical properties of themembrane,with no speciﬁc requirements for a par-
ticular chemical structure. One example of this is tafazzin, an acyl
transferase that enriches cardiolipinwith linoleoyl (18:2) chains, yet ex-
hibits no substrate speciﬁcity for particular acyl chains [2]. In contrast to
this, there are very speciﬁc structural requirements of certain enzymes
for particular lipids, such as the speciﬁcity of certain lipoxygenases for
arachidonic acid [3].
Another indication that acyl chains play a functional role is the obser-
vation that they are very unevenly distributed among lipids of different
classes, i.e. among lipids containing different headgroups. Even within
the same organism, the acyl chain composition of speciﬁc lipids is differ-
ent in different organs. Furthermore, changes in the acyl chain composi-
tion of a lipid can affect its function and even lead to disease states. The
factors determining the speciﬁc incorporation of particular acyl chains in
certain lipids and the consequences of the loss of this speciﬁcity are only
recently attractingmore attention. One lipid class that is highly enriched
in speciﬁc acyl chains is phosphatidylinositol (PI).
1.1. Properties of phosphatidylinositols
Phosphatidylinositol (PI) is composed of a glycerol backbone, with an
inositol ring and a phosphate at the sn−3position and two acyl chains es-
teriﬁed at the sn−1 and sn−2 positions [4]. The inositol ring can be phos-
phorylated at multiple positions, which can yield seven unique species
known as phosphoinositides (PIPns) (Fig. 1) [5]. PIPns are spatially and
temporally maintained in distinct sub-cellular compartments through
the concerted actions of PI-kinases and phosphatases. For example,
phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2) is primarily enriched
in the plasma membrane (PM), whereas phosphatidylinositol-4-
phosphate (PI4P) is high in the Golgi [6,7].Table 1
Examples of polyunsaturated fatty acids.
Common name Lipid name Chemical name
Omega-3 fatty acids
Alpha-linolenic acid (ALA) 18:3 (n−3) All-cis-9,12,15-octadecatrienoic acid
Eicosatrienoic acid (ETE) 20:3 (n−3) All-cis-11,14,17-eicosatrienoic acid
Eicosatetraenoic acid (ETA) 20:4 (n−3) All-cis-8,11,14,17-eicosatetraenoic acid
Eicosapentaenoic acid
(EPA, timnodonic acid)
20:5 (n−3) All-cis-5,8,11,14,17-eicosapentaenoic
acid
Docosapentaenoic acid
(DPA, clupanodonic acid)
22:5 (n−3) All-cis-7,10,13,16,19-docosapentaenoic
acid
Docosahexaenoic acid
(DHA, cervonic acid)
22:6 (n−3) All-cis-4,7,10,13,16,19-docosahexaenoic
acid
Omega-6 fatty acids
Linoleic acid 18:2 (n−6) All-cis-9,12-octadecadienoic acid
Gamma-linolenic acid
(GLA)
18:3 (n−6) All-cis-6,9,12-octadecatrienoic acid
Dihomo-gamma-linolenic
acid (DGLA)
20:3 (n−6) All-cis-8,11,14-eicosatrienoic acid
Arachidonic acid (AA) 20:4 (n−6) All-cis-5,8,11,14-eicosatetraenoic acid
Docosapentaenoic acid
(osbond acid)
22:5 (n−6) All-cis-4,7,10,13,16-docosapentaenoic
acidPIPn species control several different cellular processes such as the
regulation of ion channels, actin-cytoskeleton dynamics, vesicular trans-
port, endocytosis, exocytosis and signal transduction pathways [8–10].
The interactions between PIPns and their downstream targets are numer-
ous and complex, so only an overview of their interactions will be
discussed. Simply, downstream targets of PIPns are recruited and/or acti-
vated at speciﬁc sub-cellular compartments through phosphoinositide
binding motifs. These interactions are primarily mediated through a
combination of electrostatic and hydrophobic interactions [11]. The role
of the headgroup structure in these interactions is currently better under-
stood, however evidence is accumulating to indicate that the acyl chain
composition also has an important role. Currently, ten phosphoinositide
binding motifs have been characterized, each showing speciﬁcity for dif-
ferent PI species [12]. For example, although the adaptor proteins AP1
and AP2 bind similar cargo proteins, AP1 binds PI4P and localizes in the
Golgi. AP2 on the other hand, binds PI(4,5)P2 and is enriched in the PM
[13,14].1.2. Phosphatidylinositol biosynthesis
The de-novo biosynthesis of PI occurs exclusively in the endoplasmic
reticulum (ER) and beginswith the precursors, glycerol-3-phosphate or
dihydroxyacetonephosphate (Fig. 2) [15]. Thesemolecules undergo two
sets of acylations through the actions of acyltransferases; the ﬁrst
acylation forms lysophosphatidic acid (LPA), whereas the second acyla-
tion step produces phosphatidic acid (PA) [16]. PA can also be formed
through the actions of diacylglycerol kinase (DGK) on diacylglycerolFig. 1. The structure and production of phosphatidylinositol. Phosphatidylinositol is
composed of a glycerol backbone (blue), two acyl chains at the sn−1 and sn−2 positions
(red) and an inositol headgroup (green). The hydroxyl groups can be phosphorylated at
positions 3, 4 and 5, which can yield up to seven unique phosphoinositide species. The
production of these species is tightly regulated through the actions of PI kinases and
phosphatases. PIPn species can also be interconverted, as indicated by the arrows.
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lipids, such as phosphatidylcholine. PA is then converted to CDP-
diacylglycerol (CDP-DAG), through CDP-DAG synthases (CDS),
from PA and CTP. In the ﬁnal step, PI synthase (PIS) catalyzes the
coupling of CDP-DAG to myo-inositol to form PI [15]. Once formed
in the ER, the PI is distributed to other locations in the cell, including
the plasma membrane (PM) resulting in the recycling of lipid
between the PM and the ER forming the PI cycle as described below.
1.2.1. Acyl-chain enrichment
PI is highly enriched at both sn−1 and sn−2 positions with speciﬁc
acyl chains; the major species being 1-stearoyl-2-arachidonoyl PI (18:0
sn−1/20:4 sn−2 PI) [17–19]. Depending on the particular tissue, up to
70% of all PI species have this acyl chain composition [18]. Interestingly,
studies have shown that the acyl chain composition of PI synthesized
through the de novo pathway, in contrast to the lipids in the PI cycle,
contains mainly saturated and monounsaturated acyl chains [20–23].
So, how do PI species become highly enriched with a different acyl
chain composition? There are two potential enzymatic processes that
can result in this selective acyl chain incorporation. One involves the cy-
clical pathwayknown as the PI cycle [24]. The substrate speciﬁcity of the
enzymes involved in this cycle can lead to acyl chain enrichment. Since
the processes are cyclical and all the lipid intermediates of the cycle are
regenerated, any partial enrichment occurring in one cycle will be mul-
tiplied by the number of times the cycle repeats. The second pathway,
known as the Land's cycle, involves acyl chain remodeling of PI species
through acylation and deacylation reactions [25].
1.2.2. The PI cycle
Upon stimulation by growth factors, PI-speciﬁc isoforms of
phospholipase C (PI-PLC) cleave PI(4,5)P2 in the PM into inositol tri-
phosphate (IP3) and DAG (Fig. 2) [24]. IP3 is a water soluble signalingFig. 2. Themultiple pathways of PI synthesis. The de novo synthesis of PI beginswith G3P, which
The de novo pathway takes place in the ER. The PI cycle also contributes to PI synthesis, feeding P
which is formed by PI(4,5)P2 cleavage. PI(4,5)P2 is re-synthesized in the PM. The PI cycle requi
and marked with an *.molecule which can activate Ca2+ channels and release Ca2+ from the
ER. DAG itself is a potent lipid secondary messenger which can activate
several different DAG-binding proteins such as PKC, PKD, Munc13 and
RasGRP [26]. The DAG that is a component of the PI cycle is phosphory-
lated to PA by DGK in either the ER or the PM [27]. This PA can then be
fed into the PI cycle [24]. PA is also produced by the action of phospho-
lipase D, but this PA is not enriched in stearoyl–arachidonoyl acyl chains
and therefore must be segregated from the PI cycle. The PI produced in
the ER is then transported to the PM, undergoing two phosphorylations
to generate PI(4,5)P2 [27]. The cyclical nature of the PI cycle suggests
that acyl chain enrichment of PI species could occur if one or more
enzymes show acyl chain speciﬁcity.
1.2.3. The Land's cycle
All phospholipids undergo acyl chain remodeling through the ac-
tions of acyltransferases and phospholipases. This process is collectively
known as the Land's cycle (Fig. 3) [25,28–30]. Remodeling allows cer-
tain lipids to maintain speciﬁc acyl chain compositions, which is impor-
tant for signaling functions. Several classes of enzymes that are needed
for remodeling have been characterized. Lysophosphatidylinositol
acyltransferases are enzymes that transfer an acyl group from acyl-
CoA to the sn−2 position of a lysophospholipid [31]. Other enzymes re-
quired for remodeling include the phospholipase A1 and A2 families,
which cleave acyl chains off phospholipids [32,33]. The Land's cycle
could result in acyl chain enrichment through the selective incorpora-
tion and/or removal at acyl chains of PI.
2. Evidence for the importance of enrichment of DAG with speciﬁc
acyl chains
The DAG species produced from PC has distinct acyl chain composi-
tions compared with the DAG produced from PI(4,5)P2 [34,35]. DAGis converted to PA. CDS1/2 converts PA to CDP-DAG and PI is formed through PIS enzymes.
A into the de novo pathway. PA is produced through the phosphorylation of DAG by DGKε,
res both the ER and PM. Enzymes that have arachidonoyl speciﬁcity are highlighted in red
Fig. 3. The Land's cycle of acyl chain remodeling for PA and PI species. The acyl chains of PI
can be remodeled through phospholipases and acyltransferases. DDHD1 is a phospholi-
pase A1 that has dual speciﬁcity for PA and PI. Other phospholipases, both A1 and A2,
cleave acyl chains of phospholipidswith varying speciﬁcity for the headgroup. Conversely,
acyltransferases can transfer an acyl chain to lysophospholipids from other phospholipids
or from acyl-CoA, creating new phospholipids. Both phospholipases and acyltransferases
are critical as they not only maintain lipid asymmetry, but also regulate the levels of
phospholipids, lysophospholipids and fatty acids. Enzymes that may contribute to
arachidonoyl enrichment in PI are highlighted in red and marked with an *.
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sn−2 position. The principle form of DAG produced from PI(4,5)P2, as a
step in the PI cycle, is 1-stearoyl-2-arachidonoyl glycerol (SAG) formed
by the action of PI-PLC on PI(4,5)P2. The nature of the acyl chains on
DAG determines its potency in stimulating protein kinase C (PKC)
[36]. Sustained PKC activation has been shown to be oncogenic and con-
tributes to malignant phenotypes seen in cancers [37,38]. Only polyun-
saturated DAG species (derived from PI(4,5)P2) were shown to be able
to bind and activate PKC (α, ε, δ) isoforms both in vitro and in vivo
[34,35,39]. In particular, SAG is more effective in activating PKCδ
compared with other DAG species. The relative activating potency of
different DAG species is different for different PKC isoforms [35], show-
ing that the acyl chain composition of DAG affects its signaling proper-
ties. Other evidence of acyl chain speciﬁcity of DAG comes from recent
studies of the activation of caged DAGs with different acyl chains [40].
It was demonstrated that the photoactivation to liberate SAG, and not
other DAGs, resulted in a massive increase of intracellular Ca2+ levels.
This can be understood in terms of the PI cycle. SAG is an intermediate
in the PI cycle and its liberation will activate the cycle. This is because
in biochemical cycles all of the intermediates in the cycle act as catalysts
for the cycle because they are regenerated by the cycle itself.While all of
the lipid intermediates are regenerated by the cycle, the overall process
utilizes nucleotide triphosphates and inositol to generate IP3, a ligand
for opening calcium channels in the ER and raising the intracellular
levels of Ca2+. Thus, these experiments tie in speciﬁc acyl chains with
signaling resulting from the PI cycle.
3. Phospholipids as precursors of bioactive lipids
Phospholipids themselves can act as signaling molecules, as well as
being precursors for other bioactive lipids through the action of
phospholipases. For example, arachidonic acid, liberated by hydrolysis
of phospholipids, is a critical precursor for a large family of inﬂammato-
ry compounds known as eicosanoids [41,42]. Free fatty acids and
lysophospholipids have roles as lipid signaling agents or as precursors
to such lipids. However, fatty acids and lysolipids also have detergent-
like properties and are toxic to cells at high concentration. Hence they
are maintained at low concentrations in the cell. They are produced as
signaling agents from phospholipid precursors and the quantity offatty acids and lysolipids that can be generated is highly dependent on
the presence of certain acyl chains in the phospholipid. Hence the
amount of phospholipids in a cell with certain acyl chains, in particular
arachidonoyl and docosahexanoyl chains, will determine the ability to
form downstream lipid signaling molecules.
3.1. Arachidonic acid as a precursor of bioactive lipids
Polyunsaturated acyl chains also serve as precursors to several
classes of lipid modulations. These lipid modulators play critical roles
in processes such as inﬂammation, blood pressure, immune function
and neuroprotection [43,44]. Arachidonic acid, derived from the sn−2
acyl chain of PI and phosphatidylethanolamine (PE), is a precursor to
a family of oxygenated derivatives known as eicosanoids. Eicosanoids
encompass a large family of lipid molecules, most of which are pro-
inﬂammation [41,42]. Chronic inﬂammation often results in fever and
is implicated in several diseases, such as arthritis, atherosclerosis and
cancer [41,44,45].
3.2. Polyunsaturated acids (PUFA) as precursors of anti-inﬂammatory
lipids
Many of the eicosanoid lipids are pro-inﬂammatory. Polyunsaturat-
ed fatty acids are also precursors for anti-inﬂammatory lipids. Arachi-
donic acid is an n−3 PUFA. Another common n−3 PUFA are
eicosapentaenoic acid (20:5) that is a precursor for E-resolvins, and
docosahexaenoic acid (22:6) that is a precursor for D-resolvins and for
protectin D1 [46]. All of these products are anti-inﬂammatory and
reverse the inﬂammation caused by eicosanoids [47].
3.3. 2-Arachidonoylglycerol (2-AG) as a signaling lipid
2-Arachidonoylglycerol (2-AG) is derived from the cleavage of SAG
by DAG lipases [48]. 2-AG is a known ligand for the CB1 and CB2 canna-
binoid receptors, which are implicated in the regulation of food intake,
neurotransmitter release and pain [49–51]. Aberrant 2-AG signaling
has also been clinically linked to Alzheimer's disease in patients [52].
4. Enzymes contributing to the enrichment of lipids with
arachidonoyl groups
While several different PUFA have speciﬁc roles in lipid signal-
ing, in this review we wish to focus on the role of arachidonoyl en-
richment which is important for the lipid intermediates of the PI
cycle, as well as for the generation of eicosanoids. Several enzymes
show arachidonoyl speciﬁcity and could play signiﬁcant roles in PI's
acyl chain enrichment. In the following sections, we will examine
several of these enzymes, with speciﬁc emphasis on the physiolog-
ical signiﬁcance of DGKε, phosphatidylinositol-4-phosphate 5-
kinase (PI4P5K) and lysophosphatidylinositol acyltransferase 1
(LPIAT1).
4.1. Diacylglycerol kinase epsilon (DGKε)
DGKε catalyzes the phosphorylation of DAG to PAusingATP as a phos-
phate donor [53]. Out of the tenmammalian isoforms of DGK, DGKε is the
only isoform that shows speciﬁcity for the acyl chains of the substrate
[54]. In vitro and in vivo experiments have shown that DGKε prefers
DAG substrates with an sn−1 stearoyl and an sn−2 arachidonoyl group,
the species being SAG (18:0 sn−1/20:4 sn−2 DAG) [54–56].
Since the acyl chain composition of SAG is also predominant in PI spe-
cies, it is believed that DGKε is committed to PI re-synthesis. We should
point out that although DGKε can contribute signiﬁcantly to acyl chain
enrichment in PI, it is not the only factor. There are tissues in which
DGKε is not highly expressed, yet they still can synthesize PI. However,
in tissues such as the brain in which DGKε is highly expressed, acyl
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larly large. Studies in DGKε−/−MEFs have indicated that there is a rough-
ly 30% decrease in the content of PA and PI in the plasma membrane of
these cells as compared to wild type MEFs [24]. Similar lipidomic exper-
iments in DGKε−/− MEFs have also shown a reduction in the levels of
both stearoyl and arachidonoyl contents in PI lipids [17,54]. The decrease
in arachidonoyl content also extends to other lipid classes, including PC
[17]. This change in arachidonoyl-PC would be expected to increase
cell cycling and promote Akt activation [1]. Over-expression of DGKε
in porcine aortic endothelial cells, that would phosphorylate SAG to
make the corresponding PA, results in signiﬁcant decreases in polyun-
saturated DAGs [34]. In DGKε−/−mouse models, electrical stimulation
of these mice resulted in decreases in the levels of arachidonoyl-
PI(4,5)P2 and free arachidonic acid [57]. Thus it appears that DGKε not
only contributes to the re-synthesis of PI, but also increases its
arachidonoyl content.
The functional importance of DGKε in PI-synthesis and acyl chain en-
richment has been demonstrated through several studies, most notably
in neural function. DGKε appears to regulate seizure susceptibility and
long termpotentiation through PI signaling [43,57,58]. Using electrocon-
vulsive shocks, DGKε−/− mice were shown to have reduced levels of
free arachidonic acid, 20:4-DAG and 20:4-PI(4,5)P2. These lipids were
also shown to take longer to return to resting levels. Physiologically,
DGKε−/− mice were shown to be resistant to electroconvulsive shock
and kindling, conditions tied to deﬁciencies in long-term neural poten-
tiation. DGKε−/−mice also showed a lack of morphological changes in
hippocampal glial cells, including hypertrophied cell bodies and elon-
gated processes [57]. The involvement of the PI-cycle and DGKε in
kindling and long-term potentiation makes it an attractive target for
epilepsy.
DGKε also appears to be an attractive target for the attenuation of
Huntington's disease. Blocking DAG-activated transient receptor poten-
tial has been shown to block Huntington's neurotoxicity [59]. Mutant
Huntington (Htt) protein also appears to bind subsets of PIPns more
strongly that the wild type protein. Inhibition of DGKε using siRNAs re-
duced caspase activity and striatal toxicity of aHdh111Q/111Q cell line. Sim-
ilarly, DGKε protein levels were also increased in the striatum of HD
transgenicmice, which suggests a potential role for this protein in the ob-
served toxicity of mutant Htt.
Recent work has also identiﬁed roles for DGKε in renal function; mu-
tations in the DGKE gene were identiﬁed in membranoproliferative-like
glomerular microangiopathy (MPGN) and atypical hemolytic–uremic
syndrome (HUS) [60,61]. Both MPGN and HUS present with several
renal phenotypes, such as thrombosis and frequently leading to renal
failure. DAG signaling is believed to be a key for the development of
these diseases through the production of pro/anti-thrombic factors and
the regulation of slit diaphragm function in endothelial cells and
podocytes, respectively. These mutant DGKε variants were primarily lo-
calized to its catalytic domain and were shown to result in increasing
DAG levels.
DGKε restores cardiac dysfunction and improves survival under
chronic pressure overload by controlling cellular DAG levels and
TRPC-6 expression. It is suggested thatDGKεmaybe a novel therapeutic
target to prevent cardiac hypertrophy and progression to heart failure
[62].4.2. CDP-diacylglycerol synthase 2 (CDS2)
CDS2 is involved in the next step of PI re-synthesis after DGKε, cata-
lyzing the conversion of PA to CDP-diacylglycerol [63]. There are two
CDS isoforms, both of which are found in the ER [64,65]. CDS2 appears
to show substrate speciﬁcity for PA species, preferentially acting on 1-
stearoyl-2-arachidonoyl PA in vitro [66]. It is not currently known
whether CDS1 also shows the same speciﬁcity. There is evidence that
antidepressant drugs affect CDS activity [67].4.3. Phosphatidylinositol-4-phosphate 5-kinase (PI4P5K)
PI4P5K phosphorylates PI4P to PI(4,5)P2 using ATP as a phosphate
donor. These enzymes are mainly responsible for the production of
PI(4,5)P2 and are the rate limiting step in the PI cycle [68]. PI(4,5)P2 reg-
ulates several critical processes such as actin polymerization and re-
organization, vesicular trafﬁcking, neurotransmitter release and signal
transduction pathways [69,70]. Deregulation of PI(4,5)P2 metabolism
has been demonstrated in awide range of neuronal disorders, including
Down syndrome, psychiatric disorders, Alzheimer's and Huntington's
disease [71]. Additionally, PI(4,5)P2 serves as a precursor to PIP3, a
potent signaling lipid implicated in cell survival, growth and migration.
PIP3 is up-regulated in several cancers and PTEN, a PIP3 phosphatase is
frequently mutated in cancers [72].
There are three PI4P5K isoforms (α, β, γ), all of which have been
shown to prefer SAPI4P (18:0–sn−1/20:4–sn−2 PI4P) and SOPI4P
(18:0–sn−1/18:1–sn−2 PI4P) species when compared to DPPI4P
(16:0–sn−1/16:0–sn−2 PI4P) [55,73]. Kinetic analysis also shows that
these isoforms have the highest activity for SAPI4P, with the difference
in selectivity being largest for the γ isoform [73]. PI4P5Ks also show acyl
chain speciﬁcity for its lipid activator, themajor activator being unsaturat-
ed PA species, such as DAPA (20:4–sn−1/20:4–sn−2 PA) [73]. Thus there
appears to be more arachidonoyl speciﬁcity for the PA activation of
PI4P5K than there is for the PI4P substrate of this enzyme [24,39,54].
Through its production of PI(4,5)P2, PI4P5Ks play critical roles in
many physiological processes; like DGKε and LPIAT1, these enzymes
play especially critical roles in neural function and development. For ex-
ample, PI4P5Kα is involved in ganglioside-stimulated astrocytes, help-
ing to contribute and modulate the cell's inﬂammatory response [74].
Additionally, the α isoform was also shown to mediate TLR-dependant
inﬂammation in microglial cells [75]. Prolonged inﬂammation by astro-
cytes is also recognized to play a role in the progression of neurodegen-
erative diseases [76]. It is currently not known whether regulation of
these inﬂammatory processes is due to PI(4,5)P2's acyl chain composi-
tion or through interaction with PI(4,5)P2 binding interaction.
PI4P5Kγ was shown to be important for both cardiovascular devel-
opment and neuronal development, being essential for cell junction for-
mation in myocardiocytes and neural tube closure in the cranial region
of mice [77]. Mutations in PI4P5Kγ were found to be present in Lethal
Congenital Contracture Syndrome, a disease characterized by muscle
contractures, wasting and atrophy [78]. A cluster of PI-metabolizing
genes has also been mapped to chromosomal regions linked to psychi-
atric diseases [78]. It has been suggested that these enzymes may play a
potential role in the progression of these diseases; however, no evi-
dence for this correlation exists.
4.4. Lysophosphatidylinositol acyltransferase 1 (LPIAT1)
LPIAT1, also known asmembrane boundO-acyltransferase containing
domain 7 (also referred to as MBOAT7), catalyzes the transfer of an acyl-
CoA to lysoPI [79]. As an acyltransferase, LPIAT1 is involved in the Land's
cycle of acyl chain remodeling. Recently, it was shown that LPIAT1 has a
high preference for arachidonoyl-CoA [79]. It is not know whether
LPIAT1 also shows preference for particular lyso-PI species as this species
was not varied. However, LPIAT1's arachidonoyl speciﬁcity contributes to
both the production and the enrichment of arachidonoyl-PI.
Recently, two papers have characterized LPIAT1−/− KO mice and
have demonstrated that this enzyme is critical for neural function.
Both studies showed that knocking out LPIAT1 resulted in a signiﬁcant
decrease in arachidonoyl-containing PI, and PI(4,5)P2 [80,81]. LPIAT1
appears to be the major arachidonoyl-CoA acyltransferase, as loss of
this enzyme resulted in an almost complete loss of activity in the
brain, liver, kidney and testis of mice. LPIAT1 also appears to be critical
for neural development of mice; LPIAT−/− mice were viable up to
30 days after birth, but exhibited a smaller, atrophied cerebral cortex
and hippocampus. The laminal structure of the neocortex was also
Fig. 4. Channel in lipoxygenase to which arachidonic acid binds. Below the ﬁgure are the
sequences of lipoxygenase from different species, with the residues that are invariant in
evolution shown in red.
Taken from [88] with permission.
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LPIAT1 in cortical lamination [81].
4.5. DDHD domain containing 1 (DDHD1)
DDHD1belongs to a family of intracellular phospholipase A1s,which
act to remodel acyl chains [82,83]. DDHD1 cleaves the sn−1 acyl chain
of both PI and PA, forming two important bioactive lipids, LPI and LPA
[84]. LPI is an activator of a proposed cannabinoid receptor, GPR55,
which can activate ERK signaling pathways and increase intracellular
Ca2+ levels [85]. LPA too, can stimulate cell proliferation through bind-
ing several GPCRs and activating RhoGTPase [86]. DDHD1was shown to
have higher activity for cleaving PA species over PI. Although DDHD1's
substrate speciﬁcity has been poorly characterized, initial experiments
have shown that it forms arachidonoyl-LPI at a much higher rate than
stearoyl-LPI [84]. It is currently unknown whether DDHD1 shows sub-
strate speciﬁcity for its substrate's sn−1 chain or what impact this has
on PI enrichment.
5. A commonmotif for arachidonoyl speciﬁcity?
Could there be a common amino acid motif that contributes to
arachidonoyl speciﬁcity of several diverse enzymes? In the case of the
family of enzymes known as lipoxygenases, several crystal structures
have been solved that have identiﬁed a potential arachidonoyl preferring
motif [87]. Lipoxygenases catalyze the dioxygenation of arachidonic acid;
these enzymes are required for the synthesis of both inﬂammatory and
anti-inﬂammatory leukotrienes and lipoxins, respectively [88]. In crystal
structures of an 8R-lipoxygenase from Plexaura homomalla and human
5-lipoxygenase, the authors noted a U-shaped channel that allowed ara-
chidonic acid access to the catalytic site [3,88]. In lipoxygenases, the seg-
ment with the required residues forms an arched helix, with the side
chains of each of the required residues projecting into the channel
[3,88]. This motif is highly conserved in certain lipoxygenases through
evolution [88] (see Fig. 4).
We have referred to the conserved pattern of amino acid residues in
the lining of this channel as the LOX-like motif. A similar consensus
sequence I/L-X(3–4)-R-X(2)-L-X(4)-G, where X can be any amino acid res-
idue, is found not only in lipoxygenases, but also in the amino acid se-
quence of these enzymes discussed above, including DGKε, CDS2 and
LPIAT1. A recent study also concluded that the LOX-like motif is critical
for DGKε's arachidonoyl speciﬁcity [55]. Similar studies on CDS2 and
LPIAT1 also support a role for the LOX-like motif in the function of
these enzymes (K.D., unpublished results).
6. Enrichment of PI and the brain
There aremultiple factors contributing to the speciﬁc acyl chain con-
tent of PI. This includes the speciﬁcity of DGKε for SAG. This does not
mean that DGKε is the only isoform of DGK that participates in the PI
cycle. Other DGK isoforms will also phosphorylate SAG, but they are
just not speciﬁc for SAG. DGKε is preferentially expressed in certain
organs of mammals, such as the brain. Brain PI is also more highly
enriched with stearoyl–arachidonoyl forms than that of other organs.
It is likely that this is a result of the high expression of DGKε in the
brain. However, we do not believe that DGKε is essential for the function-
ing of the PI cycle, since some cells survive with minimal expression of
DGKε andDGKε-knockoutmicehave a rathermild phenotype. In addition
to DGKε, we have shown that CDS2 also has arachidonoyl-speciﬁcity that
can contribute to enrichment of this acyl chain in PI. However, it is not
known if CDS has any stearoyl speciﬁcity for the sn−1 position, nor has
it yet been determined what the role of CDS1 is with regard to acyl
chain selectivity. In the case of PI4P5K there is little acyl chain speciﬁcity
for the substrate. This is not surprising since the substrate, PI4P, as well
as the product, PI(4,5)P2, are both enriched with stearoyl–arachidonoyl
acyl chains to comparable extents. However, activation of PI4P5K by PAis acyl chain speciﬁc. This would increase the incorporation of stearoyl–
arachidonoyl acyl chains into PI because of activation of the PI cycle. In ad-
dition, LPIAT1 will further enrich PI with these acyl chains as a result of
acyl chain transfer from arachidonoyl-CoA to LPI by LPIAT1. In addition
to enzyme speciﬁcities, there could also be compartmentalization within
the cell, causing segregation of certain lipids. This has not yet been
explored.
While several defects have been associatedwith enzymes contribut-
ing to acyl chain enrichment in PI, these enzymes are frequently associ-
ated with defects in brain function. Thus, DGKε has a role in epilepsy
[57,58] and in Huntington's disease [59]. DGKε has also recently been
shown to play a role in light-dependent mechanisms in mammalian
photoreceptor cells [89]. CDS is activated by anti-depressants [67],
PI4P5K is associated with schizophrenia [90] and loss of LPIAT1 results
in severe developmental brain defects [80]. It is thus suggestive that
modulation of arachidonoyl-enrichment of PI can be developed as a
method for treating psychiatric disorders.
PI in the brain can also be a source of free arachidonic acid. It is found
that arachidonic acid enhances brain healing following injury [91] and
can reverse age-related brain decline [92].
7. Future directions
Acyl chain enrichment is a critical determinant in many of PI's
cellular processes, including activation of downstream proteins and
1507K. D'Souza, R.M. Epand / Biochimica et Biophysica Acta 1838 (2014) 1501–1508generation of precursor molecules. However, several questions remain
about acyl chain enrichment. Several of these enzymes, such as DGKε,
also show stearoyl preference at the sn−1 position [55]. However,
there have been no motifs identiﬁed that can confer this speciﬁcity.
Changes in the acyl chain at the sn−1 position are more tolerable than
at the sn−2 position [93]. What role does the sn−1 acyl chain play in
substrate recognition? Could it just serve to determine the depth of
burial of these substrates in membranes or help position the substrate
for catalysis?
Similarly, does the LOX-like motif form a similar channel in all
enzymes that show arachidonoyl speciﬁcity? There are key differences
between the substrates of lipoxygenases and enzymes involved in
PI synthesis. For one, arachidonoyl containing substrates are only
preferred substrates of enzymes involved in PI synthesis, whereas
lipoxygenases generally only show activity for arachidonic acid. The
arachidonoyl group in these substrates is also esteriﬁed to a glycerol
backbone, unlike arachidonic acid. How then does the LOX-like motif
guide these bulkier substrates to the catalytic site? The LOX-like motif
could allow transfer of the sn−2 arachidonoyl chain from the bilayer
to the catalytic site, thus extracting this group from the membrane;
however other explanations are possible.
Finally, are there similar motifs that also confer acyl chain speciﬁcity
for other enzymes involved in phospholipid synthesis? For example, PE
and PS species show high enrichment in both arachidonoyl and
docosahexanoyl acyl chains at its sn−2 position [94]. How does this
enrichment occur? Are there enzymes in PE and PS synthesis that
show dual acyl chain preference or multiple enzymes that show either
arachidonoyl or docosahexanoyl selectivity?Why don't other phospho-
lipids, like PC, show similar acyl chain enrichment?
The answers to these questions can provide insight into the incred-
ibly complex process of phospholipid biosynthesis and acyl chain
enrichment. Continued research into PI's stearoyl and arachidonoyl en-
richment can also prove invaluable, as these lipids are involved in criti-
cal biochemical processes and their alteration results in disease states.
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